Loading...

SGMT SAGIMET BIOSCIENCES INC Expansion Plans 8-K Filing

SGMT

SGMT

SAGIMET BIOSCIENCES INC

(SGMT)

2025 8-K

Show Summary

Show Summary

Product Expansion

Financial Statements

Financial Results

Investor Update

Investor Update

Financial Results

Financial Results

Appointment of Directors

Update of Investor Presenta...

Amendment to Press Release

Annual Meeting and Clinical...

Update Presentation

Financial Results Announcement

Appointment of CFO

Financial Results and Board...

Appointment of Interim Prin...

Financial Condition Update

Update and Positive Trial R...

Departure of CFO

Equity Grants to Executive ...

Earnings Report

Presentation Update

Update and Press Release

Earnings Reports

Update Presentation

Appointment of CFO

External Links:

On June 4, 2025, Sagimet Biosciences Inc. announced that its acne treatment, denifanstat, successfully met all trial endpoints in a Phase 3 study, and has also started a new Phase 1 trial for another acne treatment, TVB-3567, in the U.S.

AI Assistant

SAGIMET BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.